Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Decentralized Biomanufacturing of Circular RNA Vaccines

FY 2025-26

Summary
RNA therapeutics offer public health systems the ability to rapidly design and deliver protection against infectious disease, as seen with the COVID-19 pandemic. In addition, the precision of RNA offers new possibilities for treating cancer and neurological disorders with personalized medicine. Despite this potential, the technologies driving this revolution remain costly, relying on centralized manufacturing centers, and requiring cold-chain distribution, limiting their accessibility worldwide. We have developed a portable device designed for manufacturing protein-based drugs and laboratory reagents capable of synthesis and purification. This MANGO (MANufacturing on the GO) device successfully manufactured enzymes and during a four month diagnostic trial in South America, demonstrating the value of accessible biomanufacturing. We propose to adapt the MANGO device for automated biomanufacturing of RNA therapeutics (MANGO-R), integrating on-device RNA quality control and encapsulation in lipid nanoparticles (LNPs) for vaccine delivery. The objectives of this research are to optimize the in-vitro transcription and purification of a SARS-CoV-2 circular RNA (circRNA) vaccine prior to packaging circRNA into LNPs. Once reactions are optimized for on-demand manufacturing, they will be integrated into the MANGO-R device. Although RNA medicine holds tremendous promise, efficient delivery of therapeutics remains a critical barrier. This proof-of-concept, portable RNA vaccine manufacturing with the MANGO-R device could significantly improve personal and public health readiness.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573335
Name
Wu Bonny
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Decentralized Biomanufacturing of Circular RNA Vaccines
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Circrna Vaccines; Circular Rna; Decentralized Biomanufacturing; In-Vitro Transcription; Lipid Nanoparticle Vaccines; Lipid Nanoparticles; Pandemic Preparedness; Rna Therapeutics; Sars-Cov-2 Vaccine; Synthetic Biology
Abstract
RNA therapeutics offer public health systems the ability to rapidly design and deliver protection against infectious disease, as seen with the COVID-19 pandemic. In addition, the precision of RNA offers new possibilities for treating cancer and neurological disorders with personalized medicine. Despite this potential, the technologies driving this revolution remain costly, relying on centralized manufacturing centers, and requiring cold-chain distribution, limiting their accessibility worldwide. We have developed a portable device designed for manufacturing protein-based drugs and laboratory reagents capable of synthesis and purification. This MANGO (MANufacturing on the GO) device successfully manufactured enzymes and during a four month diagnostic trial in South America, demonstrating the value of accessible biomanufacturing. We propose to adapt the MANGO device for automated biomanufacturing of RNA therapeutics (MANGO-R), integrating on-device RNA quality control and encapsulation in lipid nanoparticles (LNPs) for vaccine delivery. The objectives of this research are to optimize the in-vitro transcription and purification of a SARS-CoV-2 circular RNA (circRNA) vaccine prior to packaging circRNA into LNPs. Once reactions are optimized for on-demand manufacturing, they will be integrated into the MANGO-R device. Although RNA medicine holds tremendous promise, efficient delivery of therapeutics remains a critical barrier. This proof-of-concept, portable RNA vaccine manufacturing with the MANGO-R device could significantly improve personal and public health readiness.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wu, Bonny
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~